The awards ceremony was held during the CataloniaBio & HealthTech Gala, shared via live streaming.
Judit Anido, president of CataloniaBio & HealthTech: “We need more success stories like Kymos. One of the biggest challenges we are facing as a sector is to consolidate the business sphere”
Barcelona, 14 October 2020 – CataloniaBio & HealthTech presented the 2020 Biosuccess Award to Kymos for its consolidation, international expansion and key role in dynamising the healthcare and life sciences sector in Catalonia as a science services company.
The awards ceremony took place during the CataloniaBio & HealthTech Gala, which this year was streamed online from Colònia Güell and held during the day due to the Covid-19 situation. The sector’s main yearly event featured Secretary of Economy of the Government of Catalonia Natàlia Mas, Director General for Research and Innovation in Health Robert Fabregat, and the CataloniaBio & HealthTech board of directors. The event was followed live by 180 entrepreneurs, executives and investors.
Kymos is a contract research organisation (CRO) that has grown along with the Catalan healthcare and life sciences ecosystem. The company was founded in Barcelona in 2001 by a group of scientists with experience at pharmaceutical companies. In 2012, Kymos kicked off a strategic plan that has positioned the company, locally and internationally, as one of the benchmark CROs for the pharmaceutical, biotechnology and veterinary industries, providing support in R&D services and quality control that is essential to bringing new drugs and advanced therapies to market. Kymos currently has 150 employees at its headquarters at Parc Tecnològic de Vallès and subsidiaries in Italy and Germany and expects to see €13 million in revenue.
Joan Puig de Dou, co-founder and CEO of Kymos, said the CataloniaBio & HealthTech Biosuccess Award “recognises how far we’ve come and our ongoing commitment to innovation and internationalisation, which has led us to have subsidiaries in Italy and Germany and clients With collaboration from With support from all over the world. It also recognises the work of all CROs, which make up a significant part of the country’s healthcare ecosystem both in terms of quantity and quality.”
In her speech, CataloniaBio & HealthTech President Judit Anido highlighted the importance of this sort of company: “We need more success stories like Kymos. As we discussed just a few days ago at the presentation of the 2020 BioRegion of Catalonia Report compiled in conjunction with Biocat, one of the greatest challenges we are facing as a sector, in order to become more competitive and attract more international investment, is to consolidate our business sphere, because it is rich and innovative but still only has a few medium and large companies ‘made in Catalonia’. So, CataloniaBio & HealthTech and Biocat aim to boost strategic alliances and the capacity of mature local companies like Kymos to act as a driving force over the next three years.
Previous editions of the award have gone to Oryzon (2015), Minoryx Therapeutics and Palobiofarma (2016), STAT-Dx and Mosaic Biomedicals (2017), Anaconda Biomed and Mind the Byte (2018) and Ysios Capital and Antonio Parente (2019).
The 2020 CataloniaBio & HealthTech Gala was made possible thanks to collaboration from Asabys Partners and Genesis Biomed and the support of ACCIÓ.
About CataloniaBio & HealthTech
CataloniaBio & HealthTech has more than 160 member companies and leading knowledge stakeholders in R&D in the healthcare and life sciences sector in Catalonia. Its mission is to help the business sphere generate new solutions that improve people’s health, as well as positioning Catalonia (alongside ACCIÓ, Biocat and other stakeholders) as one of the top health hubs in the world.
More information: CataloniaBio & HealthTech Gemma Escarré (Communications Manager) M. 667 76 15 24 comunicacio@cataloniabioht.org
